



FOLATE ANCHORED SAQUINAVIR ENTRAPPED PLGA NANOPARTICLES: STABILITY STUDY

Ruchi Singh^{1*}, Smita Banerjee¹, and N. K. Jain^{2,3}

¹Department of Zoology, Dr. H. S. Gour University, Sagar, 470003, India.

²Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar, 470003, India.

³School of Pharmaceutical Sciences, Rajiv Gandhi Technical University, Bhopal, 462036, India.

Article Info

Received 29/07/2016

Revised 16/08/2016

Accepted 19/08/2016

Keywords :-

Nanoparticles,
preformulation, stability,
polylactide co-glycolide.

ABSTRACT

Polymers are the most commonly explored materials for constructing nanoparticle-based drug carriers. Polymeric nanoparticles can be easily manipulated without the loss of their physical, chemical and biological properties. Freeze-drying of nanoparticles has been considered as a good technique to improve the long-term stability. In this study, we have described stability study of formulations relative to pure drug and stability analysis at different storage conditions. Our main aim in the present investigation was to confirm drug Saquinavir (SQV), polymer Poly(lactide co-glycolide) (PLGA), ligand Folic acid (FA) characteristics and determine stability of Saquinavir (SQV), polymer (PLGA) and synthesized PEGylated PLGA NPs & SQV-loaded FA anchored PEGylated PLGA NPs for tumor targeting. Results: The drug is stable at normal storage medium condition and targeted nanoparticles were found to be most stable at the refrigerated conditions of storage. The developed formulation can be successfully used as potential delivery vehicle for delivery of SQV.

INTRODUCTION

Developing an efficient drug delivery system has been the area of interest amongst the researchers in the past two decades. Polymers are the most commonly explored materials for constructing nanoparticle-based drug carriers with controlled drug release and increased aqueous solubility [1,2] because they have higher affinity for preferential accumulation in certain solid tumors through leaky endothelial tissue surrounding the tumor through EPR effect [3,4]. Polymeric nanoparticles can be easily manipulated without the loss of their physical, chemical and biological properties. The most promising approach is the surface modification of the carrier by dysopsonic polymer such as poly (ethylene glycol) (PEG) [5,6].

The nanoparticulate delivery systems not only tend to increase the stability of drugs but also are able to control the release of drug molecules over a longer period [7].

In this study, stability study for SQV, PLGA polymer, synthesized folate ligand via a poly(ethylene glycol) spacer (PEG) and SQV loaded non-targeted PLGA NP were performed for the targeted delivery of SQV-FOL (Folate) decorated nanoparticles for targeting to tumors [8]. Folic acid (FA) has chosen as targeting moiety because it participates in the biosynthesis of nucleotide bases and are available in pteroyl-L-glutamic acid, pteroyl-L-glutamate and pteroyl mono glutamic acid forms. Folate receptors (FRs) have been frequently over-expressed in a wide range of tumors and generally present in caveolae membrane protein [9-11]. Folic acid retains its receptor-binding and endocytotic properties when covalently linked to a wide variety of molecules [12].

Corresponding Author

Ruchi Singh

Email: - ruchi1084@gmail.com

Research Article



The principle can be used to greatly improve the function of the nanoparticles in cancer therapy through the attachment of tumor specific targeting moieties, directed at cell surface markers unique to the cancer cell.

In the previous study we have developed and characterized SQV-loaded FA anchored PEGylated PLGA NPs for tumor targeting [2].

The purpose of the present work was to evaluate the comparative stability of the SQV, PLGA polymer, SQV loaded PLGA and SQV loaded FA anchored PLGA nanoparticles, after 3 months at different conditions.

MATERIALS & METHODS

In this study following materials were used.

Saquinavir was obtained as a gift sample from Hoffman La Roche (Mannheim, Germany). Di methyl sulfoxide (Rankem), Folic acid (Himedia), Poly (D, L-Lactide –Co-Glycolide) (lactide:glycolide 50:50, mol wt 40,000-75,000) (Sigma), Poly ethylene glycol bis amine (Sigma), Phosphate buffer saline tablets pH 4 (Himedia), Phosphate buffer saline tablets pH 7 (Himedia), sodium azide (Himedia) All reagents and solvents were analytical grade and were used as received.

Stability studies of drug

SQV (10mg) was tested for stability preserved in 10ml of buffer solution (PBS, pH 7.4) with 0.1 % (w/v) sodium azide for a period of three months on storing it at three different temperature refrigerating temperature ($4 \pm 2^{\circ}\text{C}$), room temperature ($25 \pm 2^{\circ}\text{C}$) and elevated temperature ($37 \pm 2^{\circ}\text{C}$). The Drug was stored in amber coloured screw capped vials in dark and colourless vials in light via separately at $4 \pm 2^{\circ}\text{C}$, $25 \pm 2^{\circ}\text{C}$ and $37 \pm 2^{\circ}\text{C}$ for one month, two month and three months.

Vials were placed in refrigerator for $4 \pm 2^{\circ}\text{C}$, humidity control chambers (REMI, Mumbai, India) for $25 \pm 2^{\circ}\text{C}$ and incubator (YSI-438 Yorco Incubator Bacteriological, New Delhi, India) $37 \pm 2^{\circ}\text{C}$. The samples were analysed initially and periodically after one, two and three months under following parameters.

1. Media pH

The pH value of media is measured by using pH meter (Microprocessor pH meter 1012, ESICO, USA). The change of pH if any, was recorded.

2. Turbidity

Turbidity was evaluated by turbidometer (Systronics, India). The change in turbidity, if any was recorded.

3. Change in color and consistency by visual observations

It was characterized by visual observations. The change of color & consistency, if any was recorded.

Stability studies of formulations

Briefly, lyophilized SQV-PLGA and SQV-FOL-PEG-PLGA NP's (10mg) were redispersed separately in 10ml of buffer solution (PBS, 7.4) in both amber coloured and colourless screw capped vials, then labelled and preserved in PBS at pH 7.4 with 0.1 % (w/v) sodium azide for period of one, two and three months. Amber coloured and colourless vials contains nanoparticles formulation were incubated at refrigerating conditions $4 \pm 2^{\circ}\text{C}$, room temperature (RT) $25 \pm 2^{\circ}\text{C}$ and elevated temperature $37 \pm 2^{\circ}\text{C}$ for a period of one, two and three months. The stability was performed as mentioned in earlier section.

RESULT & DISCUSSION

Drug stability tested at three different temperatures in aqueous solution for three months. The drug showed relatively better stability at temperature $4 \pm 2^{\circ}\text{C}$, $25 \pm 2^{\circ}\text{C}$ comparatively than at $37 \pm 2^{\circ}\text{C}$. Stability study results have shown the best stability at $4 \pm 2^{\circ}\text{C}$ in dark (Table 1). But after 3 months storage at $4 \pm 2^{\circ}\text{C}$ in light, slight precipitation of drug was observed than dark in aqueous solution. In light more precipitation was observed at $25 \pm 2^{\circ}\text{C}$ & $37 \pm 2^{\circ}\text{C}$ shown in Table 2 and 3. The amount of precipitate was more at $37 \pm 2^{\circ}\text{C}$ than at $25 \pm 2^{\circ}\text{C}$. Drug stability study has shown that there was no remarkable change in the drug at $4 \pm 2^{\circ}\text{C}$, $25 \pm 2^{\circ}\text{C}$. This indicated that drug is stable at normal storage medium condition.

Table 1. Stability study of drug at $4 \pm 2^{\circ}\text{C}$ temperature for three months

Parameters	SQV One month		SQV Two months		SQV Three months	
	Dark Light		Dark Light		Dark Light	
pH	7.4	7.2	7.4	7.4	7.4	7.2
Turbidity	-	-	-	-	-	-
Change in color	-	-	-	-	-	-
Consistency	-	-	-	-	-	-

- = indicate no change + = indicate smaller change +++ = indicate enough change



Table 2. Stability study of drug at $25 \pm 2^{\circ}\text{C}$ temperature for three months

Parameters	SQV One month Dark Light		SQV Two month Dark Light		SQV Three month Dark Light	
	7.4	7.2	7.4	7.2	7.4	7.2
pH	7.4	7.2	7.4	7.2	7.4	7.2
Turbidity	-	-	-	-	+	+++
Change in color	-	-	-	-	-	-
Consistency	-	-	-	-	-	-

- = indicate no change + = indicate smaller change +++ = indicate enough change

Table 3. Stability study of Drug at $37 \pm 2^{\circ}\text{C}$ temperature for three months

Parameters	SQV One month Dark Light		SQV Two month Dark Light		SQV Three month Dark Light	
	7.4	7.2	7.4	7.4	7.2	7.2
pH	7.4	7.2	7.4	7.4	7.2	7.2
Turbidity	-	+	-	+	+	+++
Change in color	-	-	-	+	-	+
Consistency	-	-	-	-	-	-

- = indicate no change + = indicate smaller change +++ = indicate enough change

The prepared nanoparticles formulation tested for stability on storing them at three different temperature $4 \pm 2^{\circ}\text{C}$ and $25 \pm 2^{\circ}\text{C}$, $37 \pm 2^{\circ}\text{C}$. The parameters observed are recorded in Table 4 - 12. pH of all NPs formulations stored at $4 \pm 2^{\circ}\text{C}$ and showed no significant changes in pH, but at room temperature ($25 \pm 2^{\circ}\text{C}$) and elevated temperature ($37 \pm 2^{\circ}\text{C}$) pH was found to be decrease to some extent. It may be attributed to a change in ionic strength because of degradation of the copolymer at this temperature.

Table 4. Nanoparticles formulations stability study stored at $4 \pm 2^{\circ}\text{C}$ for one month.

Parameters	SQV-PLGA NPs One month		SQV-FOL-PEG-PLGA NPs One month	
	Dark	light	Dark	light
pH	7.4	7.2	7.4	7.4
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	-	-	-

- = indicate no change.

Table 5. Nanoparticle formulations stability study stored at $25 \pm 2^{\circ}\text{C}$ for one month.

Parameters	SQV-PLGA NPs One month		SQV-FOL-PEG-PLGA NPs One month	
	Dark	light	Dark	Light
pH	7.4	7.4	7.4	7.1
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	-	-	-

- = indicate no change

Table 6. Nanoparticles formulations stability study stored at $37 \pm 2^{\circ}\text{C}$ for one month.

Parameters	SQV-PLGA NPs One month		SQV-FOL-PEG-PLGA NPs One month	
	Dark	Light	Dark	Light
pH	7.0	6.5	6.8	6.6
Size	-	-	-	-
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	-	-	-

- = indicate no change



Table 7. Nanoparticles formulations stability study stored at $4 \pm 2^\circ\text{C}$ for two months.

Parameters	SQV-PLGA NPs Two months		SQV-FOL-PEG-PLGA NPs Two months	
	Dark	light	Dark	light
pH	7.0	6.8	7.2	7.0
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	-	-	-

- = indicate no change

Table 8. Nanoparticles formulations stability study stored at $25 \pm 2^\circ\text{C}$ for two months.

Parameters	SQV-PLGA NPs Two month		SQV-FOL-PEG-PLGA NPs Two month	
	Dark	light	Dark	light
pH	7.2	6.8	7.2	7.0
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	-	-	-

- = indicate no change

Table 9. Nanoparticles formulations stability study stored at $37 \pm 2^\circ\text{C}$ for two months.

Parameters	SQV-PLGA NPs Two month		SQV-FOL-PEG-PLGA NPs Two month	
	Dark	light	Dark	light
pH	6.8	6.5	6.5	6.4
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	+	-	-

- = indicate no change + = indicate smaller change

Table 10. Nanoparticles formulations stability study stored at $4 \pm 2^\circ\text{C}$ for three months.

Parameters	SQV-PLGA NPs Three months		SQV-FOL-PEG-PLGA NPs Three months	
	Dark	light	Dark	light
pH	6.8	6.5	7.0	6.8
Turbidity	-	-	-	-
Change in color	-	-	-	-
Consistency	-	-	-	-

- = indicate no change.

Table 11. Nanoparticles formulations stability study stored at $25 \pm 2^\circ\text{C}$ for three months.

Parameters	SQV-PLGA NPs Three month		SQV-FOL-PEG-PLGA NPs Three month	
	Dark	light	Dark	Light
pH	6.2	6.0	6.4	6.2
Turbidity	-	+	-	+
Change in color	+	++	+	++
Consistency	++	++	+	++

- = indicate no change + = indicate smaller change ++ = indicate considerable change.



Table 12. Nanoparticles formulations stability study stored at $37 \pm 2^\circ\text{C}$ for three months.

Parameters	SQV-PLGA NPs Three month		SQV-FOL-PEG-PLGA NPs Three month	
	Dark	Light	Dark	light
pH	6.0	5.8	6.2	6.0
Turbidity	-	++	-	+
Change in color	+	++	-	+
Consistency	+	++	+	++

- = indicate no change + = indicate smaller change ++ = indicate considerable change.

No significant change in color and consistency were observed in case of both drug loaded PLGA NPs at $4 \pm 2^\circ\text{C}$, $25 \pm 2^\circ\text{C}$, $37 \pm 2^\circ\text{C}$ after one months of storage. Slight change in color and consistency was observed at $4 \pm 2^\circ\text{C}$ after three months storage. Turbidity and consistency increased with increasing temperature. Nanoparticle formulations stored at $37 \pm 2^\circ\text{C}$ showed considerable change in color and consistency due to high temperature.

Ligand anchored drug loaded (SQV-FOL-PEG-PLGA) NPs stored at $37 \pm 2^\circ\text{C}$, for three months showed high turbidity than drug loaded (SQV-PLGA) NPs, when kept both in dark and light. The storage at $37 \pm 2^\circ\text{C}$ might have induced polymerization tendency of free groups by degradation of structure which resulted in the appearance of precipitation and turbidity. The NPs formulation (SQV-PLGA NPs & SQV-FOL-PEG-PLGA NPs) showed better stability with regards to pH, turbidity, change in color and consistency when stored at dark as well as refrigerated conditions. Thus storage of NPs formulation in amber colored vials as well as refrigerated conditions is recommended.

In this study SQV loaded FOL targeted nanocarriers have been developed to circumvent some of

these problems, to reduce side effects of SQV. SQV nontargeted PLGA and folate targeted PLGA NPs were synthesized and optimum conditions for storage of nanoformulations have been found.

CONCLUSION

The focus in the present study has been on the stability of nanocarriers and molecules that can selectively target tumors, to explore anticancer activity in selected antiviral drug and to highlight the challenges in translating some of the basic research to the clinic.

Stability studies of drug and drug loaded nanoparticles for three months revealed that NPs formulation stored at $4 \pm 2^\circ\text{C}$ in dark were more stable than those stored at $25 \pm 2^\circ\text{C}$ or $37 \pm 2^\circ\text{C}$ in light.

ACKNOWLEDGMENTS

The author would like to acknowledge Department of Science and Technology (DST), New Delhi, India for providing the Fellowship to carry out this research work. Additionally, author would also like to acknowledge F. Hoffman-La Roche, Mannheim (Germany) for providing the gift sample of Saquinavir.

REFERENCES

- Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK. (2010). Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. *Int J Pharm*, 393, 185–96.
- Singh R, Kesharwani P, Mehra NK, Singh S, Banerjee S, Jain NK. (2015). Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity. *Drug Dev Ind Pharm*, 41, 1888-1901.
- Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. (2011). Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. *Nanomed*, 7, 295–304.
- Kesharwani P, Tekade RK, Jain NK. (2015). Dendrimer generational nomenclature: the need to harmonize. *Drug Discov Today*, 20, 497-499.
- Jain A, Jain K, Kesharwani P, Jain NK. (2013). Low density lipoproteins mediated nanoplatforms for cancer targeting. *J Nanopart Res*, 15, 1-38.
- Clawson C, Ton L, Aryal S, Fu V, Esener S, Zhang L. (2011). Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding. *Langmuir*, 27, 10556-61.
- Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Preat V. (2012) PLGA-based nanoparticles: An overview of biomedical applications. *J Control Rel*, 161,505-22.
- Kesharwani P, Tekade RK, Jain K, Jain NK. (2014). Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. *Biomaterials*, 35, 5539–48.
- Birdhariya B, Kesharwani P, Jain NK. (2014). Effect of surface capping on targeting potential of folate decorated poly(propylene imine) dendrimers. *Drug Dev Ind Pharm*, 41, 1393-9.
- Mehra NK, Jain NK. (2013). Development, characterization and cancer targeting potential of surface engineered carbon nanotubes. *J Drug Target*, 21, 745–58.



11. Thakur S, Kesharwani P, Tekade RK, Jain NK. (2015). Impact of pegylation on biopharmaceutical properties of dendrimers. *Polymer*, 59, 67–92.
12. Jain S, Kesharwani P, Tekade RK, Jain NK. (2014). One platform comparison of solubilization potential of dendrimer with some solubilizing agents. *Drug Dev Ind Pharm*, 41, 722-727.

